XML 19 R5.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Series B Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Series C Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Series B Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series C Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2016 $ 10,986           $ 2     $ 388,789     $ 1,258 $ (379,063)
Balance (in shares) at Dec. 31, 2016             2,170,789              
Share-based compensation 753                 753        
Issuance of common stock under employee stock purchase plan 1                 1        
Issuance of common stock under employee stock purchase plan (in shares)             120              
Sale/Issuance of common stock 12,716 $ 8,767         $ 1     12,715 $ 8,767      
Sale/Issuance of common stock (in shares)         10,000   1,223,708              
Conversion of Convertible Preferred Stock into common stock   23           $ 3     20      
Conversion of Convertible Preferred Stock into common stock (share)         (7,569)     2,270,632            
Issuance of common stock as part of Azaya Therapeutics acquisition, net 2,311                 2,311        
Issuance of common stock as part of Azaya Therapeutics acquisition, net (shares)             117,324              
Beneficial conversion feature related to Series B Convertible Preferred Stock   3,977                 3,977      
Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock   $ (3,977)                 $ (3,977)      
Foreign currency translation adjustment and accumulated other comprehensive income 129                       129  
Net loss (22,686)                         (22,686)
Balance at Dec. 31, 2017 $ 13,000           $ 6     413,356     1,387 (401,749)
Balance (in shares) at Dec. 31, 2017 5,782,573     2,431     5,782,573              
Share-based compensation $ 355                 355        
Sale/Issuance of common stock 1,624   $ 3,041       $ 5     1,619   $ 3,041    
Sale/Issuance of common stock (in shares)           6,723 4,608,453              
Conversion of Convertible Preferred Stock into common stock     8           $ 4     4    
Conversion of Convertible Preferred Stock into common stock (share)         (1,320) (3,228)   396,045 4,043,343          
Beneficial conversion feature related to Series B Convertible Preferred Stock     2,487                 2,487    
Accretion of beneficial conversion feature related to Series B Convertible Preferred Stock     $ (2,487)                 $ (2,487)    
Foreign currency translation adjustment and accumulated other comprehensive income (169)                       (169)  
Net loss (12,634)                         (12,634)
Balance at Dec. 31, 2018 $ 5,225           $ 15     $ 418,375     $ 1,218 $ (414,383)
Balance (in shares) at Dec. 31, 2018 5,782,573     4,606     14,830,414